Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 311

1.

Denosumab in men receiving androgen-deprivation therapy for prostate cancer.

Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; Denosumab HALT Prostate Cancer Study Group.

N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11.

2.

Denosumab for prevention of fractures in postmenopausal women with osteoporosis.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial.

N Engl J Med. 2009 Aug 20;361(8):756-65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11. Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914.

3.

Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.

Smith MR, Saad F, Egerdie B, Szwedowski M, Tammela TL, Ke C, Leder BZ, Goessl C.

J Urol. 2009 Dec;182(6):2670-5. doi: 10.1016/j.juro.2009.08.048.

4.

Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.

Egerdie RB, Saad F, Smith MR, Tammela TL, Heracek J, Sieber P, Ke C, Leder B, Dansey R, Goessl C.

Prostate Cancer Prostatic Dis. 2012 Sep;15(3):308-12.

5.

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

Ellis GK, Bone HG, Chlebowski R, Paul D, Spadafora S, Smith J, Fan M, Jun S.

J Clin Oncol. 2008 Oct 20;26(30):4875-82. doi: 10.1200/JCO.2008.16.3832. Epub 2008 Aug 25.

6.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.

Bone HG, Bolognese MA, Yuen CK, Kendler DL, Wang H, Liu Y, San Martin J.

J Clin Endocrinol Metab. 2008 Jun;93(6):2149-57. doi: 10.1210/jc.2007-2814. Epub 2008 Apr 1.

PMID:
18381571
7.

[Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].

Kudlacek S, Puntus T.

Wien Med Wochenschr. 2012 Sep;162(17-18):380-5. doi: 10.1007/s10354-012-0106-z. Epub 2012 Aug 9. Review. German.

PMID:
22875632
8.

Denosumab in postmenopausal women with low bone mineral density.

McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ; AMG 162 Bone Loss Study Group.

N Engl J Med. 2006 Feb 23;354(8):821-31.

10.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy.

Kendler DL, Roux C, Benhamou CL, Brown JP, Lillestol M, Siddhanti S, Man HS, San Martin J, Bone HG.

J Bone Miner Res. 2010 Jan;25(1):72-81. doi: 10.1359/jbmr.090716.

11.

Denosumab: in cancer treatment-induced bone loss.

Muir VJ, Scott LJ.

BioDrugs. 2010 Dec 1;24(6):379-86. doi: 10.2165/11203310-000000000-00000. Review.

PMID:
21043545
12.

Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass.

Bone HG, Bolognese MA, Yuen CK, Kendler DL, Miller PD, Yang YC, Grazette L, San Martin J, Gallagher JC.

J Clin Endocrinol Metab. 2011 Apr;96(4):972-80. doi: 10.1210/jc.2010-1502. Epub 2011 Feb 2.

PMID:
21289258
13.

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.

Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS.

J Urol. 2013 Jan;189(1 Suppl):S45-50. doi: 10.1016/j.juro.2012.11.016.

PMID:
23234631
14.

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women.

Wensel TM, Iranikhah MM, Wilborn TW.

Pharmacotherapy. 2011 May;31(5):510-23. doi: 10.1592/phco.31.5.510. Review.

PMID:
21923432
15.

Toremifene to reduce fracture risk in men receiving androgen deprivation therapy for prostate cancer.

Smith MR, Morton RA, Barnette KG, Sieber PR, Malkowicz SB, Rodriguez D, Hancock ML, Steiner MS.

J Urol. 2010 Oct;184(4):1316-21. doi: 10.1016/j.juro.2010.06.022. Epub 2010 Aug 17. Erratum in: J Urol. 2011 Jan;185(1):365.

16.

Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer.

Morgans AK, Hancock ML, Barnette KG, Steiner MS, Morton RA, Smith MR.

J Urol. 2012 Mar;187(3):889-93. doi: 10.1016/j.juro.2011.10.136. Epub 2012 Jan 15.

17.

Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.

Ryan CW, Huo D, Demers LM, Beer TM, Lacerna LV.

J Urol. 2006 Sep;176(3):972-8; discussion 978.

PMID:
16890673
18.

Teriparatide or alendronate in glucocorticoid-induced osteoporosis.

Saag KG, Shane E, Boonen S, Marín F, Donley DW, Taylor KA, Dalsky GP, Marcus R.

N Engl J Med. 2007 Nov 15;357(20):2028-39.

19.

A 24-month study evaluating the efficacy and safety of denosumab for the treatment of men with low bone mineral density: results from the ADAMO trial.

Langdahl BL, Teglbjærg CS, Ho PR, Chapurlat R, Czerwinski E, Kendler DL, Reginster JY, Kivitz A, Lewiecki EM, Miller PD, Bolognese MA, McClung MR, Bone HG, Ljunggren Ö, Abrahamsen B, Gruntmanis U, Yang YC, Wagman RB, Mirza F, Siddhanti S, Orwoll E.

J Clin Endocrinol Metab. 2015 Apr;100(4):1335-42. doi: 10.1210/jc.2014-4079. Epub 2015 Jan 21.

PMID:
25607608
20.

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N.

J Urol. 2003 Jun;169(6):2008-12.

PMID:
12771706
Items per page

Supplemental Content

Write to the Help Desk